Randox Biosciences on Familial Hypercholesterolemia (FH)
Randox Biosciences on Familial Hypercholesterolemia (FH)
What is Familial Hypercholesterolemia?
Familial Hypercholesterolemia (FH) is a genetic condition which is passed down from the parents’ genes. The British Heart Foundation has highlighted that FH is caused by a genetic mutation which means the liver is unable to remove excess ‘bad’ cholesterol (LDL), therefore, the LDL level in the blood remains high.2 Someone who suffers with FH would have high cholesterol from birth which can cause other health issues including heart and circulatory disease.
Heart UK states that more than 260,000 people in the UK may have FH. However, less than 10% of this number have been diagnosed and therefore, may not be aware of their condition.3 However, to date there are no clear symptoms if someone has FH until it is considered too late.
Familial Hypercholesterolemia (FH) symptoms
- Swollen tendons/fatty lumps on the knuckles of your hands, at the back of your ankles and knees
- Cholesterol deposits around the eye-lids (looks like pale and yellowish patches)
- Grey-white cholesterol deposits around the corneas
If untreated, about 50% of men and 30% of women with FH will develop coronary heart disease by the time they are 55. More worryingly, on average in the UK, one person a day with FH has a heart attack. About a third of people don’t survive their first heart attack, and many who do survive will have damaged hearts.
The good news is that a 2008 study part-funded by the BHF found that people with FH who are diagnosed and treated before they develop heart disease generally live as long as people who don’t have FH. That’s why it is vitally important to get diagnosed as early as possible.
How Randox Biosciences can help
Randox Biosciences offers the Familial Hypercholesterolemia (FH) Arrays I & II to help encourage early diagnosis with rapid turnaround time. This allows results to be reported within days compared with NHS waiting lists which can be substantially longer.
Our two arrays are rapid, simple and accurate which enables the simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes.
The mutational status can be determined rapidly from a single test, with a reduced need for confirmatory testing. Genetic analysis for FH mutations also allows for more accurate diagnosis compared to lipid profiling.
Familial Hypercholesterolemia (FH) Arrays I & II:
LDLR – 38 mutations
APOB – 1 mutation
PCSK9 – 1 mutation
Contact us
To find out more about the products that we offer, email us info@randoxbiosciences.com
AACC 19
Join us for AACC 2019!
Randox Laboratories will be attending AACC from the 6th – 8th August 2019. Our innovative diagnostic solutions have been developed with consolidation and economy in mind, providing cost savings whilst using pioneering technology.
Diagnostics is our passion. We are dedicated to developing solutions that not only meet your needs, but that are of the highest quality, the most reliable and the most cost-effective. We look forward to meeting you in the Anaheim Convention Centre at stand 1101.
New Products
Acusera Infectious Disease Serology Controls
Randox Quality Control are pleased to announce the launch of our new Infectious Disease Serology Internal Quality Controls. Our portfolio includes Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more.
All samples are provided in a user-friendly, liquid ready-to-use format. This significantly reduces preparation time and the risk of pipetting errors.
There is approximately 1 million people in the USA living with HIV and around 15% of them are unaware they are infected (CDC, March 2019). Furthermore, the Centers for Disease Control and Prevention (CDC) estimate that around 39,000 new HIV infections are reported per year.
The impact of not only HIV but all infectious diseases is getting much greater. Therefore, laboratories now play a much more important role in providing accurate test results. This is a key component in controlling the spread of infections.
Reporting a false positive result has its own obvious implications, however, what about the consequences of reporting a false negative. This can be just as devastating to a person in terms of the treatment they will receive and even personal lifestyle changes for the patient in question.
Daytona+
At this year’s AACC, Randox are pleased to announce 510 (K) clearance from the U.S. Food and Drug Administration for the RX daytona+ clinical chemistry analyzer. Renowned for quality and reliability, the RX series leads the way with the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, diabetes and veterinary testing. Guaranteeing real cost savings through consolidation of routine and specialized tests onto a single platform, the RX series of analyzers offers excellence in patient care, delivering unrivalled precision, accuracy and reliability.
The RX daytona+ fully automated, benchtop, clinical chemistry analyzer is capable of performing high quality testing including emergency STAT sampling and boasts a combined throughput of 450 tests per hour including ISE. The most versatile chemistry analyzer in its class, the RX daytona+ presents laboratories with a range of benefits offering optimum performance, unrivalled uptime, flexibility, efficiency and functionality.
Randox Stroke Biochip
The Randox Stroke Biochip is a rapid and highly sensitive blood test that will complement and enhance existing CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.
Using Randox revolutionary patented Biochips, the Randox Stroke Biochip provides a unique solution for simultaneous detection of multiple stroke biomarkers from a single sample, facilitating fast and accurate classification of stroke patients in an emergency setting.
Benefits of the Randox Stroke Biochip
> Multiplex biochip for rapid stroke classification in under 30 minutes from a single plasma sample
> Complements and enhances existing CT scanning ensuring fast and accurate diagnosis
> Fast and accurate diagnostic classification between ischaemic and haemorrhagic stroke
> Simple 2 step process from sample entry to results
> Ensures better outcomes guaranteeing timely therapeutic intervention
The new Evidence+
The fully automated Evidence+ analyzer is set to truly revolutionize laboratories worldwide. Continuing to provide high standards of quality, efficiency and reliability, the fully automated batch immunoanalyzer simultaneously detects multiple drugs and drug metabolites from a single sample.
The Evidence+ analyzer enables both efficient and cost-effective testing whilst providing accurate and reliable results to larger high throughput laboratories.
Enhance your Cardiac Testing Panel with sPLA2-IIA!
Randox are pleased to announce the new automated assay for sPLA2-IIA mass. sPLA2-IIA is thought to be the most highly expressed enzyme from the secretory phospholipase A2 family. sPLA2-IIA is expressed in the normal arterial wall and its expression is readily up-regulated by inflammatory stimuli. It’s production of fatty acids and biologically active phospholipids plays an important role in platelet, monocyte, and endothelial activation, processes known to be critical steps in atherogenesis.
Meet CLIA requirements with accuracy and ease
Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.
Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment. Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.
What can we offer?
Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. We provide a variety of services and products to numerous industries including clinical laboratories, biopharma and academic research institutes.
Our revolutionary multiplex Biochip Array Technology includes multiplex protein immunoassays and multiplex nucleic acid arrays, and is delivered via the award winning Evidence range of analysers. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format.
Vivalytic the newest offering from Randox Biosciences brings innovation to the Molecular Diagnostic industry providing tests for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform is capable of both Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required making Vivalytic a unique space-saving, hygienic solution for Molecular Diagnostic testing.
Leading provider of true third-party controls
With over 390 parameters available in our Acusera range, choice and flexibility is guaranteed. Moreover, the availability of truly independent third-party controls coupled with the added advantages of highly accurate target values, excellent stability and unparalleled quality will enhance performance, save valuable time and minimize waste in any laboratory. Our comprehensive range of multi-analyte controls have been uniquely developed with user convenience in mind. By combining more than 100 parameters in a single vial, laboratories can significantly reduce the need for multiple, costly single analyte controls.
Online QC software with real-time peer group statistics
Designed to help you efficiently review QC data from multiple laboratory instruments on one centralized platform, Acusera 24.7 allows quick and easy identification of QC failures and emerging trends.
Unique access to live peer group updates will reduce time and money spent troubleshooting, helping you to instantly discover if an issue is isolated to your lab or a widespread problem. The added benefit of automatically generated statistics including Sigma Scores, Measurement Uncertainty & Total Error as well as fully interactive charts & reports will enable quick and easy performance monitoring.
Meet CLIA requirements with accuracy and ease
Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.
Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment. Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.
RIQAS – The World’s Largest International PT scheme
With over 45,000 laboratory participants in more than 133 countries, the Randox International Quality Assessment Scheme (RIQAS) is truly the largest international PT provider in the world. Our comprehensive product offering currently covers over 360 parameters across 33 flexible programmes. Each RIQAS programme contains a unique combination of parameters meaning laboratories can significantly reduce the number of individual programmes required whilst increasing efficiency and reducing costs. Further benefits to a laboratory include accreditation to ISO 17043:2010, frequent reporting, reduced parameter options and access to comprehensive yet user-friendly reports.
Molecular Infectious Disease Controls
Qnostics is a leading manufacturer of Third Party Quality Control solutions for Molecular Infectious Disease testing. Supplying microbiology/virology laboratories, molecular diagnostic assay manufacturers, EQA providers, pharmaceutical and CRO organisations for over a decade.
Designed to meet the demand of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT), the Qnostics Molecular Infectious Disease range comprises hundreds of characterised viral, bacterial and fungal targets covering a wide range of Transplant Associated Diseases, Respiratory Infections, Blood Borne Viruses, Sexually Transmitted Infections, Gastrointestinal Diseases and Central Nervous System Diseases.
Randox Reagents are internationally recognised as being of the highest quality, offering reliable and rapid results. Our product portfolio consists of 111 clinical chemistry assays, covering a range of testing panels, including: antioxidants, diabetes, drugs of abuse testing, cardiology and lipids, specific proteins, therapeutic drug monitoring and veterinary testing.
Randox are continuously striving to improve diagnostic solutions worldwide. As a result, Randox have produced 29 niche and superior performance assays, including: 5th Generation Bile Acids, Adiponectin, Aldolase, Copper, Cystatin C, D-3-Hydroxybutyrate, G6PDH, H-FABP, Lipoprotein (a), NEFA, HDL Cholesterol, sdLDL Cholesterol, Total Antioxidant Status and Zinc.
Renowned for quality and reliability, the RX series leads the way with the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, veterinary and diabetes testing. Guaranteeing real cost savings through consolidation of routine and specialised tests onto a single platform, the RX series of analysers delivers excellence in patient care, offering unrivalled precision, accuracy and reliability.
RX misano
The RX misano semi-automated analyser has been developed with the user in mind by incorporating a responsive touch-screen display. The sleek ergonomic design boasts intuitive user-friendly software allowing for test menu personalisation and ease of use. The RX misano is capable of high standard, precise results at a competitive price per test.
RX monaco
The RX monaco is a fully automated solution for low to mid volume clinical chemistry testing offering the ultimate in convenience, performance and confidence. At optimal configuration, the RX monaco performs 170 tests per hour providing cost effective, high quality testing.
RX daytona +
The RX daytona+ is a fully automated, benchtop, clinical chemistry analyser capable of performing high quality testing, with a combined throughput of 450 tests per hour, for accurate results you can trust. The most versatile analyser in its class, the RX daytona+ combines robust hardware and intuitive software with the world leading RX series test menu for unrivalled performance with direct HbA1c testing capabilities.
RX imola
The RX imola is a cost-effective system that delivers consistent high-quality results. Capable of handling the workload of a medium to high throughout laboratory and a combined throughput of 560 tests per hour, the RX imola provides rapid, comprehensive testing on a small footprint analyser with direct HbA1c testing capabilities. The RX imola is a fully automated system with random access and STAT sampling functionality, boosting productivity and saving time when it matters most
RX modena
Capable of performing up to 1,200 tests per hour, with direct HbA1c testing capabilities, the RX modena consolidates all your assay requirements onto one intuitive platform. The RX modena boasts icon based, interactive touch-screen technology adding a modern flair to your laboratory.
Randox Toxicology offer the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to ever changing market influences and develop assays for current and novel drug trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.
Evidence series immunoassay analysers guarantee cost-effective, highly accurate and flexible testing solutions. Having been developed to work with patented Biochip Array Technology, this precision multiplex testing platform allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
This multiplex system delivers an unrivalled increase in patient information, offering a more in-depth diagnostic profile with each patient sample. This further analysis places the focus on the diagnosis, and on improving patient outcomes.
Want to know more?
Contact us or book a meeting with us
View our list of scientific posters that will be on display at AACC
Development of a Duplex Biochip Assay for the Simultaneous Detection of Anti-thyroglobulin and Anti-thyroid Peroxidase Antibodies on the Fully Automated Evidence Evolution Analyser | Display time: 12.30pm-1.30pm | Presenter: A. Jennings (RCLS)
Development of a New Biochip Based Immunoassay for the Detection of Parathyroid Hormone Applied to the Evidence Evolution Analyser | Display time: 12.30pm-1.30pm | Presenter: H. Winter (Randox R&D)
Human Based Liquid Frozen Multi-Analyte Linearity Verification Material Covering Five Levels of Lipid Profile Components for Accurate Assessment of the Test System Reportable Range | Display time: 12.30pm-1.30pm | Presenter: L. Adams (Randox Laboratories Ltd.)
Development and Evaluation of a Fully-Automated Multiplex Molecular Test for the Detection of Common Causative Agents of Urinary Tract Infections | Display time: 12.30pm-1.30pm | Presenter: M.K. Higgings (Randox R&D Molecular Biology)
Evaluation of a Latex Enhanced Immunoturbidimetric Assay Kit for the Rapid Direct On-Board Measurement of Glycated Haemoglobin (%HbA1c) on the RX daytona + Analyser | Display time: 12.30pm-1.30pm | Presenter: E. Lenehan (Randox Laboratories Ltd)
Development of Monoclonal Antibodies to Chromogranin A, a Biomarker for Neuroendocrine Dysfunction | Display time: 12.30pm – 1.30pm | Presenter: H. Winter (Randox R&D)
Development of Monoclonal Antibodies to Pancreastatin, a Biomarker for Neuroendocrine Dysfunction | Display time: 12.30pm – 1.30pm | Presenter: E. Mathers (Randox R&D)
Development of New Biochip Arrays for the Determination of Five Biomarkers Related to Acute Kidney Injury Applied to the Evidence Investigator Analyser | Display time: 12.30pm-1.30pm | S. O’Donnell (Randox Teoranta R&D)
Alzheimer’s Disease testing on the Randox Evidence Series
What is Alzheimer’s Disease?
Alzheimer’s Disease is a progressive disease and is one of the most common kinds of dementia.
Our brains are made up of billions of tiny nerve cells which connect to each other. However, if you have Alzheimer’s Disease the connections between the cells are lost, which results in the loss of brain tissue and causes nerve cells to die1.
The brain is responsible for sending signals between cells. Those who suffer with Alzheimer’s have less ‘chemical messengers’ in their brain, so the signals are not passed on as well1.
The statistics of those who suffer with dementia is increasingly high and the figure is set to rise in the foreseeable future. Over 850,000 people are living with dementia in the UK. Studies states that one million people in the UK will have dementia in 2025 and this will increase to two million by 2050.2
Symptoms of Alzheimer’s Disease
The symptoms of Alzheimer’s disease are divided into 3 main stages; early symptoms, middle-stage symptoms and later symptoms.
In the early stages, the main symptom of Alzheimer’s disease is memory lapses which can increase anxiety or agitation. In the early stages, it is often mistaken that the person is forgetful and aren’t aware they are suffering with Alzheimer’s. The typical signs are listed below:3
- forget about recent conversations or events
- misplace items
- forget the names of places and objects
- have trouble thinking of the right word
- ask questions repetitively
- show poor judgement
- become less flexible and more hesitant to try new things
As the disease progresses, the symptoms will gradually get worse. Memory problems will get worse which can make it difficult for the person who suffers with the disease to remember names of their loved ones, recent events and even remember birthdays and anniversaries. More symptoms such as the following will develop;3
- increasing confusion and disorientation – for example, getting lost, or wandering and not knowing what time of day it is
- obsessive, repetitive or impulsive behaviour
- delusions or feeling paranoid and suspicious about carers or family members
- problems with speech or language
- disturbed sleep
- changes in mood
- difficulty performing simple tasks and may need additional support e.g. help with eating, getting dressed etc.
In the later stages of Alzheimer’s disease, the symptoms become increasingly severe and patients will need full-time care and assistance. It will be problematic for the individual to do basic everyday tasks such as getting changed, going to the toilet, getting washed and feeding themselves. They could lose their speech, and have difficulty eating and swallowing which can result in severe weight loss.
How Randox can help
Randox want to help. Our Evidence immunoanalyser has revolutionised laboratory screening worldwide with the capability to process 3,960 tests per hour and a sample capacity of 360. We offer the Apolipoprotein E4 (ApoE4) Array for Alzheimer’s genetic risk assessment, which is a research use-only product developed for the Evidence Investigator. The ApoE4 Array measures both total ApoE protein levels and ApoE4 protein levels directly from plasma samples and using a ratio can classify patients as negative or positive for ApoE4. In turn we can then assess their risk for the development of Alzheimer’s disease.
For further information about the Randox Alzheimer’s Array or our Evidence Investigator, please email info@randoxbiosciences.com
Cystic Fibrosis Awareness Month at Randox Biosciences
May is National Cystic Fibrosis (CF) Awareness Month. The purpose of having the awareness month is to educate and raise additional awareness to the public about the horrible disease and how it affects those who suffer. According to the Cystic Fibrosis Foundation, more than 30,000 people are living with cystic fibrosis. More than 75% of these people are diagnosed in their early childhood 1.
What is CF?
Cystic Fibrosis is a genetic, life-threatening disease which affects the respiratory and digestive system. A person with CF is born with the condition and therefore it is not possible to catch it from someone else. The gene affected by CF controls the movement of salt and water in and out of cells, which results in a build-up of thick sticky mucus in the lungs, digestive system and other organs. This causes a wide range of challenging symptoms affecting the entire body.2
Symptoms of CF:
There are many symptoms to Cystic Fibrosis which can make life for someone who suffers with CF challenging. The build-up of sticky mucus in the lungs can make breathing difficult and clog up the pancreas which as a result can increase the risk of developing a lung infection or worse, death. This can make it difficult for those who have CF to absorb nutrients from food properly and therefore they must eat more calories to avoid malnutrition. Other symptoms include the following:3
- recurring chest infections
- wheezing, coughing, shortness of breath and damage to the airways (bronchiectasis)
- difficulty putting on weight and growing
- jaundice
- diarrhoea, constipation, or large, smelly poo
- a bowel obstruction in new-born babies (meconium ileus) – surgery may be needed
Complications of CF:
3People with CF also have a higher risk of developing other conditions. These include:
- weak and brittle bones (osteoporosis)– medicines called bisphosphonates can sometimes help
- diabetes– insulin and a special diet may be needed to control blood sugar levels
- nasal polyps and sinus infections – steroids, antihistamines, antibiotics or sinus flushes can help
- liver problems
- fertility problems – it’s possible for women with CF to have children, but men won’t be able to father a child without help from fertility specialists (see a doctor or fertility specialist for more advice)
4There is no cure for CF, but with improved treatment and management people with Cystic Fibrosis are living longer. It’s thought that children born with CF nowadays are likely to live to an average age of over 50 years old.
How we can help:
Randox Biosciences offer the Vivalytic with the Chronic Lung Disease cartridge, in combination with our intelligent Biochip Array Technology which detects 132 pathogens. The 132 species are simultaneously detected across this 320 Array including bacterial, viral, fungal targets and an antibiotic resistance marker from a single sputum sample!
For more information at info@randoxbiosciences.com or visit us at: wwww.randoxbiosciences.com
- https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/
- https://www.blf.org.uk/support-for-you/cystic-fibrosis/what-is-it
- https://www.nhs.uk/conditions/cystic-fibrosis/
- https://www.nhsinform.scot/illnesses-and-conditions/lungs-and-airways/cystic-fibrosis
Africa Health 2019
Join us for Africa Health 2019!
Randox Laboratories will be attending Africa Health from the 28th – 30th May 2019. Our innovative diagnostic solutions have been developed with consolidation and economy in mind, providing cost savings whilst using pioneering technology.
Diagnostics is our passion. We are dedicated to developing solutions that not only meet your needs, but that are of the highest quality, the most reliable and the most cost-effective. We look forward to meeting you in the Gallagher Convention Centre in Johannesburg , at our stand #4.D16.
What can we offer?
Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. We provide a variety of services and products to numerous industries including clinical laboratories, biopharma and academic research institutes.
Our revolutionary multiplex Biochip Array Technology includes multiplex protein immunoassays and multiplex nucleic acid arrays, and is delivered via the award winning Evidence range of analysers. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format.
Vivalytic
Vivalytic the newest offering from Randox Biosciences brings innovation to the Molecular Diagnostic industry providing tests for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform is capable of both Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required making Vivalytic a unique space-saving, hygienic solution for Molecular Diagnostic testing.
Acusera
Leading provider of true third-party controls
With over 390 parameters available in our Acusera range, choice and flexibility is guaranteed. Moreover, the availability of truly independent third-party controls coupled with the added advantages of highly accurate target values, excellent stability and unparalleled quality will enhance performance, save valuable time and minimise waste in any laboratory. Our comprehensive range of multi-analyte controls have been uniquely developed with user convenience in mind. By combining more than 100 parameters in a single vial, laboratories can significantly reduce the need for multiple, costly single analyte controls.
Acusera 24.7
Online QC software with real-time peer group statistics
Designed to help you efficiently review QC data from multiple laboratory instruments on one centralised platform, Acusera 24.7 allows quick and easy identification of QC failures and emerging trends.
Unique access to live peer group updates will reduce time and money spent troubleshooting, helping you to instantly discover if an issue is isolated to your lab or a widespread problem. The added benefit of automatically generated statistics including Sigma Scores, Measurement Uncertainty & Total Error as well as fully interactive charts & reports will enable quick and easy performance monitoring.
Acusera Verify
Meet CLIA requirements with accuracy and ease
Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.
Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment. Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.
The World’s Largest International EQA scheme
With over 45,000 laboratory participants in more than 133 countries, the Randox International Quality Assessment Scheme (RIQAS) is truly the largest international EQA provider in the world. Our comprehensive product offering currently covers over 360 parameters across 33 flexible programmes. Each RIQAS programme contains a unique combination of parameters meaning laboratories can significantly reduce the number of individual programs required while increasing efficiency and reducing costs. Further benefits to a laboratory include accreditation to ISO 17043:2010, frequent reporting, reduced parameter options and access to comprehensive yet user-friendly reports.
Molecular Infectious Disease Controls
Qnostics is a leading manufacturer of Third Party Quality Control solutions for Molecular Infectious Disease testing. Supplying microbiology/virology laboratories, molecular diagnostic assay manufacturers, EQA providers, pharmaceutical and CRO organisations for over a decade.
Designed to meet the demand of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT), the Qnostics Molecular Infectious Disease range comprises hundreds of characterised viral, bacterial and fungal targets covering a wide range of Transplant Associated Diseases, Respiratory Infections, Blood Borne Viruses, Sexually Transmitted Infections, Gastrointestinal Diseases and Central Nervous System Diseases.
Molecular External Quality Control
QCMD is a world leading External Quality Assessment (EQA) / Proficiency Testing (PT) scheme, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases. With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the field of infectious disease testing.
EQA participants receive an individual report outlining their performance relative to their method and technology groups. A supplementary report may be commissioned – this includes any additional relevant information regarding the annual EQA distribution, as well as scientific expert commentary and feedback on the overall results within that distribution.
Randox Reagents are internationally recognised as being of the highest quality, offering reliable and rapid results. Our product portfolio consists of 113 clinical chemistry assays, covering a range of testing panels, including: antioxidants, diabetes, drugs of abuse testing, cardiology and lipids, specific proteins, therapeutic drug monitoring and veterinary testing.
Randox are continuously striving to improve diagnostic solutions worldwide. As a result, Randox have produced 29 niche and superior performance assays, including: 5th Generation Bile Acids, Adiponectin, Aldolase, Copper, Cystatin C, D-3-Hydroxybutyrate, G6PDH, H-FABP, Lipoprotein (a), NEFA, HDL2/3 Cholesterol, sdLDL Cholesterol, Total Antioxidant Status and Zinc.
Enhance your Cardiac Testing Panel with sPLA2-IIA!
sPLA2-IIA is thought to be the most highly expressed enzyme from the secretory phospholipase A2 family. sPLA2-IIA is expressed in the normal arterial wall and its expression is readily up-regulated by inflammatory stimuli. It’s production of fatty acids and biologically active phospholipids plays an important role in platelet, monocyte, and endothelial activation, processes known to be critical steps in atherogenesis.
Renowned for quality and reliability, the RX series leads the way with the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, veterinary and diabetes testing. Guaranteeing real cost savings through consolidation of routine and specialised tests onto a single platform, the RX series of analysers delivers excellence in patient care, offering unrivalled precision, accuracy and reliability.
RX misano
The RX misano semi-automated analyser has been developed with the user in mind by incorporating a responsive touch-screen display. The sleek ergonomic design boasts intuitive user-friendly software allowing for test menu personalisation and ease of use. The RX misano is capable of high standard, precise results at a competitive price per test.
RX monaco
The RX monaco is a fully automated solution for low to mid volume clinical chemistry testing offering the ultimate in convenience, performance and confidence. At optimal configuration, the RX monaco performs 170 tests per hour providing cost effective, high quality testing.
RX daytona +
The RX daytona+ is a fully automated, benchtop, clinical chemistry analyser capable of performing high quality testing, with a combined throughput of 450 tests per hour, for accurate results you can trust. The most versatile analyser in its class, the RX daytona+ combines robust hardware and intuitive software with the world leading RX series test menu for unrivalled performance with direct HbA1c testing capabilities.
RX imola
The RX imola is a cost-effective system that delivers consistent high-quality results. Capable of handling the workload of a medium to high throughout laboratory and a combined throughput of 560 tests per hour, the RX imola provides rapid, comprehensive testing on a small footprint analyser with direct HbA1c testing capabilities. The RX imola is a fully automated system with random access and STAT sampling functionality, boosting productivity and saving time when it matters most
RX modena
Capable of performing up to 1,200 tests per hour, with direct HbA1c testing capabilities, the RX modena consolidates all your assay requirements onto one intuitive platform. The RX modena boasts icon based, interactive touch-screen technology adding a modern flair to your laboratory.
Randox Toxicology offer the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to ever changing market influences and develop assays for current and novel drug trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.
Evidence series immunoassay analysers guarantee cost-effective, highly accurate and flexible testing solutions. Having been developed to work with patented Biochip Array Technology, this precision multiplex testing platform allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
This multiplex system delivers an unrivalled increase in patient information, offering a more in-depth diagnostic profile with each patient sample. This further analysis places the focus on the diagnosis, and on improving patient outcomes.
Want to know more?
Contact us or book a meeting with us
EuroMedLab 2019
Join us for EuroMedLab 2019!
Randox Laboratories will be attending EuroMedLab from the 19th – 23rd May 2019. Our innovative diagnostic solutions have been developed with consolidation and economy in mind, providing cost savings whilst using pioneering technology.
Diagnostics is our passion. We are dedicated to developing solutions that not only meet your needs, but that are of the highest quality, the most reliable and the most cost-effective. We look forward to meeting you in the Barcelona International Convention Centre, at our booth No. 184.
Register your attendance at one of our industry sponsored workshops
The industry specific workshops are open to all congress attendees on a first come, first-served basis.
Development and clinical evaluation of an automated multi-analyte biochip array for rapid stroke diagnosis | Room 116 | Mon, 20 May 2019 , 14:45 – 15:45
Secreted Phospholipases A2 and Cardiovascular Risk | Room 116 | Tue, 21 May 2019 , 12:30 – 13:30
Novel Multiplex Molecular Diagnostics: A Cross-Platform Comparison | Room 117 | Tue, 21 May 2019, 14:45 – 15:45
What can we offer?
Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. We provide a variety of services and products to numerous industries including clinical laboratories, biopharma and academic research institutes.
Our revolutionary multiplex Biochip Array Technology includes multiplex protein immunoassays and multiplex nucleic acid arrays, and is delivered via the award winning Evidence range of analysers. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format.
Vivalytic
Vivalytic the newest offering from Randox Biosciences brings innovation to the Molecular Diagnostic industry providing tests for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform is capable of both Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required making Vivalytic a unique space-saving, hygienic solution for Molecular Diagnostic testing.
Join our workshop on Tuesday 21st May 2019 to learn more about molecular testing and how 44 pathogens can be tested from a single patient sample.
Acusera
Leading provider of true third-party controls
With over 390 parameters available in our Acusera range, choice and flexibility is guaranteed. Moreover, the availability of truly independent third-party controls coupled with the added advantages of highly accurate target values, excellent stability and unparalleled quality will enhance performance, save valuable time and minimise waste in any laboratory. Our comprehensive range of multi-analyte controls have been uniquely developed with user convenience in mind. By combining more than 100 parameters in a single vial, laboratories can significantly reduce the need for multiple, costly single analyte controls.
Acusera 24.7
Online QC software with real-time peer group statistics
Designed to help you efficiently review QC data from multiple laboratory instruments on one centralised platform, Acusera 24.7 allows quick and easy identification of QC failures and emerging trends.
Unique access to live peer group updates will reduce time and money spent troubleshooting, helping you to instantly discover if an issue is isolated to your lab or a widespread problem. The added benefit of automatically generated statistics including Sigma Scores, Measurement Uncertainty & Total Error as well as fully interactive charts & reports will enable quick and easy performance monitoring.
Acusera Verify
Meet CLIA requirements with accuracy and ease
Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.
Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment. Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.
The World’s Largest International EQA scheme
With over 45,000 laboratory participants in more than 133 countries, the Randox International Quality Assessment Scheme (RIQAS) is truly the largest international EQA provider in the world. Our comprehensive product offering currently covers over 360 parameters across 33 flexible programmes. Each RIQAS programme contains a unique combination of parameters meaning laboratories can significantly reduce the number of individual programs required while increasing efficiency and reducing costs. Further benefits to a laboratory include accreditation to ISO 17043:2010, frequent reporting, reduced parameter options and access to comprehensive yet user-friendly reports.
Molecular Infectious Disease Controls
Qnostics is a leading manufacturer of Third Party Quality Control solutions for Molecular Infectious Disease testing. Supplying microbiology/virology laboratories, molecular diagnostic assay manufacturers, EQA providers, pharmaceutical and CRO organisations for over a decade.
Designed to meet the demand of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT), the Qnostics Molecular Infectious Disease range comprises hundreds of characterised viral, bacterial and fungal targets covering a wide range of Transplant Associated Diseases, Respiratory Infections, Blood Borne Viruses, Sexually Transmitted Infections, Gastrointestinal Diseases and Central Nervous System Diseases.
Join our workshop on Tuesday 21st May 2019 to learn more about molecular testing and how 44 pathogens can be tested from a single patient sample.
Molecular External Quality Control
QCMD is a world leading External Quality Assessment (EQA) / Proficiency Testing (PT) scheme, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases. With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the field of infectious disease testing.
EQA participants receive an individual report outlining their performance relative to their method and technology groups. A supplementary report may be commissioned – this includes any additional relevant information regarding the annual EQA distribution, as well as scientific expert commentary and feedback on the overall results within that distribution.
Randox Reagents are internationally recognised as being of the highest quality, offering reliable and rapid results. Our product portfolio consists of 113 clinical chemistry assays, covering a range of testing panels, including: antioxidants, diabetes, drugs of abuse testing, cardiology and lipids, specific proteins, therapeutic drug monitoring and veterinary testing.
Randox are continuously striving to improve diagnostic solutions worldwide. As a result, Randox have produced 29 niche and superior performance assays, including: 5th Generation Bile Acids, Adiponectin, Aldolase, Copper, Cystatin C, D-3-Hydroxybutyrate, G6PDH, H-FABP, Lipoprotein (a), NEFA, HDL2/3 Cholesterol, sdLDL Cholesterol, Total Antioxidant Status and Zinc.
Enhance your Cardiac Testing Panel with sPLA2-IIA!
sPLA2-IIA is thought to be the most highly expressed enzyme from the secretory phospholipase A2 family. sPLA2-IIA is expressed in the normal arterial wall and its expression is readily up-regulated by inflammatory stimuli. It’s production of fatty acids and biologically active phospholipids plays an important role in platelet, monocyte, and endothelial activation, processes known to be critical steps in atherogenesis.
Join our workshop on Tuesday 21st May 2019 to learn more about sPLA2-IIA’s role in inflammatory conditions, including its prediction in cardiovascular risk.
Renowned for quality and reliability, the RX series leads the way with the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, veterinary and diabetes testing. Guaranteeing real cost savings through consolidation of routine and specialised tests onto a single platform, the RX series of analysers delivers excellence in patient care, offering unrivalled precision, accuracy and reliability.
RX misano
The RX misano semi-automated analyser has been developed with the user in mind by incorporating a responsive touch-screen display. The sleek ergonomic design boasts intuitive user-friendly software allowing for test menu personalisation and ease of use. The RX misano is capable of high standard, precise results at a competitive price per test.
RX monaco
The RX monaco is a fully automated solution for low to mid volume clinical chemistry testing offering the ultimate in convenience, performance and confidence. At optimal configuration, the RX monaco performs 170 tests per hour providing cost effective, high quality testing.
RX daytona +
The RX daytona+ is a fully automated, benchtop, clinical chemistry analyser capable of performing high quality testing, with a combined throughput of 450 tests per hour, for accurate results you can trust. The most versatile analyser in its class, the RX daytona+ combines robust hardware and intuitive software with the world leading RX series test menu for unrivalled performance with direct HbA1c testing capabilities.
RX imola
The RX imola is a cost-effective system that delivers consistent high-quality results. Capable of handling the workload of a medium to high throughout laboratory and a combined throughput of 560 tests per hour, the RX imola provides rapid, comprehensive testing on a small footprint analyser with direct HbA1c testing capabilities. The RX imola is a fully automated system with random access and STAT sampling functionality, boosting productivity and saving time when it matters most
RX modena
Capable of performing up to 1,200 tests per hour, with direct HbA1c testing capabilities, the RX modena consolidates all your assay requirements onto one intuitive platform. The RX modena boasts icon based, interactive touch-screen technology adding a modern flair to your laboratory.
Randox Toxicology offer the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to ever changing market influences and develop assays for current and novel drug trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.
Evidence series immunoassay analysers guarantee cost-effective, highly accurate and flexible testing solutions. Having been developed to work with patented Biochip Array Technology, this precision multiplex testing platform allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
This multiplex system delivers an unrivalled increase in patient information, offering a more in-depth diagnostic profile with each patient sample. This further analysis places the focus on the diagnosis, and on improving patient outcomes.
Want to know more?
Contact us or book a meeting with us
View our list of scientific posters that will be on display at EuroMedLab
Rapid simultaneous screening (less than 23 minutes) of twenty drug classes from a single whole blood sample on the biochip analyser Evidence MultiSTAT | Display time: 10.00am – 5.30pm | Presenter: P. Robinson (Randox Toxicology)
Evaluation of the effect of more frequent reporting in analytical performance through the use of an international external quality assessment scheme | Display time: 10.00am – 5.30pm | Presenter: L. Adams (Randox Laboratories Ltd.)
Development of a biochip array for the simultaneous detection of twelve cytokines on the new random access fully automated Evidence Evolution analyser | Display time: 10.00am – 5.30pm | Presenter: G. Donnellan (Randox Teoranta)
Analytical performance evaluation of an assay for the direct measurement of HbA1c in whole blood on RX series analysers of different throughput | Display time: 10.00am – 5.30pm | Presenter: E. Lenehan (Randox Laboratories Ltd)
Development of a new biochip based immunoassay for the determination of the bone formation biomarker N-terminal propeptide of type 1 collagen (P1NP) | Display time: 10.00am – 5.30pm | Presenter: H. Stott (R&D Randox Biosciences)
Development of a biochip-based immunoassay for the specific detection of the Wnt signalling antagonist DKK1 | Display time: 10.00am – 5.30pm | Presenter: H. Stott (R&D Randox Biosciences)
Development of a highly specific monoclonal antibody pair for the detection of sclerostin, a regulator of bone turnover | Display time: 10.00am – 5.30pm | A. Connolly (Randox Teoranta)
Biomarker glycosylation evaluation in pancreatic cancer utilizing biochip array technology | Display time: 10.00am – 5.30pm | A. Connolly (Randox Teoranta)
Improving stroke diagnoses with Randox Biosciences
A stroke can happen to anyone at any time. It is a serious life-threatening medical condition which occurs when the blood supply to part of the brain is cut off. It causes the brain cells to die resulting the abilities controlled by the brain such as memory and muscle control to become damaged. 1
According to the Stroke Association, strokes are considered the fourth biggest killer in the UK. There are more than 100,000 strokes each year which equals around one stroke every five minutes.2 Some people recover from the condition; however, two thirds of the survivors will have some sort of disability. 3
There are two mains types of strokes which are defined as “Ischemic strokes” and “Hemorrhagic stroke”.
Ischemic Stroke
Ischemic stroke is by far the most common kind of stroke, accounting for about 88% of all cases4. Ischemic strokes occur when there is an artery blockage which cuts off the blood supply to certain areas of the brain, which then results in brain cells being unable to make energy and dying. The arteries are vital for the brain as they bring fresh blood from the heart and lungs carrying oxygen and nutrients and taking away carbon dioxide and cellular waste. 4
Hemorrhagic Stroke
The hemorrhagic stroke is less common but is more severe as there is a higher risk of dying within the first three months. It is when a blood vessel ruptures causing a bleed inside the brain, resulting in the death of brain cells. They are responsible for 40% of all stroke deaths.5
Symptoms of Stroke
The most commons symptoms of a stroke are:
- Weakness or numbness of the face, arm, or leg on one side of the body
- Loss of vision or dimming in one or both eyes
- Loss of speech, difficulty talking, or understanding what others are saying
- Sudden, severe headache with no known cause
- Loss of balance or unstable walking, usually combined with another symptom
Many risk factors can increase your chance of having a stroke. Some life style factors include being obese/overweight, not exercising enough, heavy drinking, use of illegal drug such as cocaine, cigarette smoking, high cholesterol, diabetes, disruptive sleeping pattern and family history of having stroke or heart attack.
Preventing Stroke
Up to 80% of strokes are preventable. 3 There are simple healthy lifestyle recommendations that could decrease your chances of developing a stroke in the future which include:
- Controlling your blood pressures as it is one of the biggest preventions of developing a stroke.
- Maintaining a healthy weight through a well-balanced diet involving rich fruit and vegetables as well as decreasing the amount of cholesterol, saturated fat and sodium intake.
- Exercising regularly and staying within a good routine will also reduce your risk of having a stroke.
- Quitting tobacco usage and decreasing alohcal intake will help as well as regular usage increases the risk of having high blood pressure.
- Avoid taking illegal drugs such as cocaine as it reduces your blood flow which narrows the arteries.
Randox Biosciences offers a stroke array which works quickly to determine which type of stroke a person has experienced. Ischaemic stroke can be treated by thrombolysis and, with early usage, it can help limit stroke damage and disability.
However, inappropriate administration of thrombolytic therapy can cause serious adverse effects, including intracranial haemorrhage. Hence, there is an unmet clinical need for a rapid and highly sensitive testing that complements existing CT scanning approaches and facilitate the definitive identification of ischaemic stroke patients.
Randox’s innovative Biochip Array Technology enables simultaneous detection of eight stroke biomarkers from a single blood sample.
The eight biomarkers that can be detected in a single blood sample are:
- Glutathione S-Transferase-Pi (GSTP-Pi)
- Nucleoside Diphosphate Kinase A (NDKA)
- Parkinson Protein 7 (PARK7)
- Glial Fibrillary Acidic Protein (GFAP)
- D-Dimer
- Interleukin 6 (IL-6)
- sNFR1
- Heart Fatty Acid Binding Protein (H-FABP)
For more information email us at info@randoxbiosciences.com or visit our newly improved website: https://goo.gl/8qkYkg
- https://www.nhs.uk/conditions/stroke/
- https://www.stroke.org.uk/system/files/sotn_2018.pdf
- https://www.stroke.org/understand-stroke/what-is-stroke/stroke-facts/
- http://www.strokecenter.org/patients/about-stroke/ischemic-stroke/
- https://www.stroke.org/understand-stroke/what-is-stroke/hemorrhagic-stroke/
National Brain Awareness Week 11th – 15th March 2019
This year, National Brain Awareness Week runs from the 11th onto the 15th March 2019; a full week dedicated to brain health to increase public awareness of the progress and research of brain health.
Every single brain is unique and therefore, there are no two brains that are alike. The brain is an incredible and powerful organ which works throughout your life – starting from the womb to the end. It controls your body functioning in response to processing new information, developing new experiences and allowing you to understand and interact with the world. It contains one hundred billion nerve cells or neurons and each of the neurons can contact thousands of other cells via tiny structures called synapses. Our brains form a million new connections for every second of our lives.1
There are many conditions which can affect the brain including brain injuries, cerebrovascular injuries such as strokes or brain tumors, neurodegenerative disorders such as dementia or Parkinson’s disease, or even psychological conditions.
There is increasing evidence that the choices we make in life can have significant impacts on the health of our brain and bodies as we grow older. Doctors and scientific researchers have discovered that it’s possible to improve brain health and reduce the risk of dementia and age-related cognitive decline by making simple yet small lifestyle changes – for example, improving your physical exercise.
Physical experience is not only good for the heart but also has a positive impact on the brain as well. People who exercise regularly have a lower risk of developing Alzheimer’s disease as exercise improves blood flow and memory. Another way to improve your brain health is to get your eight hours of sleep. Poor sleeping patterns can increase your chances of developing the brain conditions highlighted above. Also, eating well and eating foods that improve brain function will go a long way – for example, berries, fish, turmeric, green tea, avocado, walnuts and even dark chocolate.
Caroline Abrahams, Director of Age UK said: ‘The changes that we need to make to keep our brains healthy are already proven to be good for the heart and overall health, so it’s common sense for us all to try to build them into our lives.’ 3
Randox Biosciences offers the Apolipoprotein E4 (ApoE4) Array. The Apolipoprotein E4 (ApoE4) Array is a research use-only product developed for the Evidence Investigator. The ApoE4 Array measures both total ApoE protein levels and ApoE4 protein levels directly from plasma samples and by using a ratio it can classify patients as negative or positive for ApoE4. In turn we can then assess their risk for the development of Alzheimer’s disease.
For further information about the Randox Alzheimer’s Array or our Evidence Investigator, please email info@randoxbiosciences.com
Randox Biosciences Launch New Website
Randox Biosciences is delighted to officially announce the launch of our new website which offers a sleek, simple yet informative platform to further your knowledge of our product range and how we can assist you.
After six months of hard work and dedication the website has a fresh look. The interactive aspect of the website provides an easy way for our visitors to learn about Randox Biosciences products and services.
The improved interactive navigation ensures the user enjoys a seamless transition through Randox Biosciences extensive range of products and services with a better experience for both mobile and desktop versions. Potential customers will be able to identify with ease which client segment they fit into – whether it be Academic Research, Biopharma or Clinical Laboratory, enjoying a fully responsive experience.
During the redesign of the Randox Biosciences website we ensured that the brand identity remained consistent throughout, incorporating the brand colours across the site. We in cooperated GIFS (Graphics Interchange Format or moving images) on the top of the homepage as the main header of the website to automatically attract visitors with a moving graphic.
The GIF represents the Biochip Array Technology and the two different diagnostics testing we offer at Randox Biosciences. The GIFs images were continued throughout the website to highlight the three industries we cater for. Brochure downloads are also available on the new website for customers to enhance their knowledge with more in-depth information of Randox’s products and services.
The incorporation of an overview video on the homepage enables website users to gain a snapshot view of Randox Biosciences products and services. The idea of presenting the video first is to allow the visitor to understand our company from a visual method rather than processing a lot of written information.
73% of consumers worldwide would prefer seeing a video than text because they are more “entertaining”.1 The video itself, captures exactly what Randox Biosciences is and what we do. A short yet effective video clearly illustrates the science behind of Randox Biosciences and how this reaches the patient through drug discovery and development.
Julie-Ann O’Hare, Director of Randox Biosciences, commented:
“I am thrilled with the final product of the website, which I hope our current and potential customers will utilise it with ease. The website is another aspect of aligning our marketing strategy and branding to ensure our messaging is clear, concise and consistent across the board. We look forward to the continuation of promoting Randox Biosciences in the digital landscape throughout 2019.”
An e-commerce section of the website is under construction for the sale of our BioReagent products, which they are very excited to launch upon completion in Q3.
Check out our new and improved website for yourself. It is available at: https://www.randoxbiosciences.com/. Also, to find out more email us at info@randoxbiosciences.com
- http://rocketium.com/academy/6-reasons-why-customers-prefer-video-ads-to-the-text-ones
Randox Alzheimer’s Array on the Evidence Investigator
Alzheimer’s disease
Alzheimer’s disease is the most common cause of dementia. It is defined as an irreversible, progressive brain disorder, in which parts of the brain are damaged over time. As this happens symptoms develop, but also get worse.
Dr. Alois Alzheimer discovered that in Alzheimer’s disease the connections between the cells and brain tissue are lost because proteins build up and form abnormal structures called “plaques” and “tangles”. 1 A healthy brain contains important chemicals which send signals between the cells, however, those who suffer with Alzheimer’s have less “chemical messengers.” Therefore, the signals don’t get passed on. 1
Risk factors
Age is the biggest risk factor. Alzheimer’s disease is more common amongst older adults. In the UK there are over 40,000 people under the age of 65 who suffer with some form of dementia. 2 Studies also state that women over the age of 65 are twice as likely to develop Alzheimer’s disease than men – although there is no clear evidence as to why.
There are two different types of Alzheimer’s. The early on-set variant of the condition is very uncommon but strikes people younger than 65. Often people with early-onset Alzheimer’s develop symptoms in their 40s or 50s. Whereas, late-onset Alzheimers is more common and affects people age 65 and older. 2
Symptoms
The disease slowly destroys memory and thinking skills. The earliest symptoms are memory lapses where they may struggle to remember recent events or learn new information, or even forget important items for day-to-day life for example, their keys, glasses or mobile phone. Memory loss due to the disease can increasingly interfere with their life as often the ability to carry out simple tasks can become a struggle. As a result, the person suffering can become anxious, irritable and can even be depressed.
In the later stages of Alzheimer’s, the symptoms become more severe. The individual will become less aware of what’s happening around them. They may have difficulties eating, walking and will require additional help and support with their daily activities from their loved ones or from a carer.
Unfortunately, there is no cure for Alzheimer’s Disease, although, there is treatment that can help manage the symptoms.
The Randox Apolipoprotein E4 Array
Randox offers The Apolipoprotein E4 (ApoE4) Array.
The Apolipoprotein E4 (ApoE4) Array is a research use-only product developed for the Evidence Investigator, which is a semi-automated benchtop immunoassay analyser which can process up to 2376 test per hour as well as up to 44 analytes screened per biochip.
The ApoE4 Array measures both total ApoE protein levels and ApoE4 protein levels directly from plasma samples and by using a ratio it can classify patients as negative or positive for ApoE4. In turn we can then assess their risk for the development of Alzheimer’s disease.
For further information about the Randox Alzheimer’s Array or our Evidence Investigator, please email info@randoxbiosciences.com
- https://www.alzheimers.org.uk/about-dementia/types-dementia/alzheimers-disease-symptoms
- https://www.nia.nih.gov/health/what-alzheimers-disease
